Pretomanid (Pretomanid) Patent Expiration, LOE Window & CMS Spending

Pretomanid (Pretomanid) by Viatris: FDA Orange Book LOE 2031-08-14, 0 AB generics, $133K 2024 CMS Part D & Medicaid spend, and 2 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorViatris
FDA Application & PathwayN212862 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2031-08-14
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$133K
2024 Medicare Part D Spend$55K
2024 Medicaid Spend$78K
Reported Wholesale Price Change (CA SB 17)2 WAC filings (max 18.0% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Viatris across sibling Meru public-data platforms.